Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
1999-4-1
|
pubmed:abstractText |
The aim of this study was to assess the GH-IGFI axis, GH receptor availability, as reflected by the levels of GH-BP, and the amount of GH-dependent IGFBP-3 in adult IDDM patients with different degrees of metabolic control. Thus, 10 adult well-controlled IDDMs (HbA1 7.8 +/- 0.4%), 10 adult non-ketotic poorly controlled IDDMs (HbA1 13.3 +/- 7%) and 14 sex- and age-matched healthy controls were subjected to two intravenous GH-RH stimulation tests with 0.1 and 1.0 microg/kg body weight respectively, and a plasma IGF-1 generation test induced by the administration of hGH. Poorly controlled IDDM patients exhibited an exaggerated GH response to 1.0 microg/kg of GH-RH when compared to healthy control subjects. Low fasting plasma IGF-1 levels and a blunted IGF-1 response to exogenously administered hGH were also found in poorly controlled IDDMs when compared to the healthy control group. GH-BP levels were significantly lower in IDDMs than in normal controls, and correlated positively with the IGF-1 generation capacity after hGH. Serum IGFBP-3 levels measured by RIA were similar in IDDM and control groups. Good glycemic control for 5.7 +/- 0.9 months did not correct the above mentioned abnormalities of the GH-IGF-1 axis. Our findings suggest that IDDM is associated with a diminished availability of GH receptors and synthesis of IGF-1. GH might then increase as a compensatory mechanism, further down-regulating liver GH receptors, and thus perpetuating the initial abnormality.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Carrier Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Growth Hormone-Releasing Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Human Growth Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor Binding...,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor I,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Somatotropin,
http://linkedlifedata.com/resource/pubmed/chemical/somatotropin-binding protein
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0018-5043
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
30
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
737-42
|
pubmed:dateRevised |
2009-2-19
|
pubmed:meshHeading |
pubmed-meshheading:9930632-Adult,
pubmed-meshheading:9930632-Blood Glucose,
pubmed-meshheading:9930632-Carrier Proteins,
pubmed-meshheading:9930632-Diabetes Mellitus, Type 1,
pubmed-meshheading:9930632-Drug Resistance,
pubmed-meshheading:9930632-Female,
pubmed-meshheading:9930632-Growth Hormone-Releasing Hormone,
pubmed-meshheading:9930632-Human Growth Hormone,
pubmed-meshheading:9930632-Humans,
pubmed-meshheading:9930632-Insulin-Like Growth Factor Binding Protein 3,
pubmed-meshheading:9930632-Insulin-Like Growth Factor I,
pubmed-meshheading:9930632-Male,
pubmed-meshheading:9930632-Receptors, Somatotropin
|
pubmed:year |
1998
|
pubmed:articleTitle |
Growth hormone-insulin-like growth factor-I axis in adult insulin-dependent diabetic patients: evidence for central hypersensitivity to growth hormone-releasing hormone and peripheral resistance to growth hormone.
|
pubmed:affiliation |
Division of Endocrinology and Nuclear Medicine, Hospital Italiano de Buenos Aires, Argentina. pfainstein@intramed.net.ar
|
pubmed:publicationType |
Journal Article
|